Sergey Shulyak
Sergey Shulyak is the General Director of DSM Group, a leading analytical and consulting company in the pharmaceutical sector. He has been instrumental in providing insights into market dynamics, especially during the recovery phase post-COVID-19. Under his leadership, the company reported an 11% growth in the pharmaceutical market in 2024, marking a significant rebound from pandemic-induced declines. Shulyak's expertise in market analysis has contributed to understanding trends in drug consumption and distribution in Russia.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Russia | 2 | 5.50 | 0.15% | +0% | 144,104,080 | 221,358 | $1,500,000 | 2,304$ |
| Totals | 2 | 144,104,080 | 221,358 | $1,500,000 | 2,304$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Russia:
Sergey Shulyak is the CEO of a marketing agency who provided insights on the financial impact of the pharmacy network closures.
5
Russia:
Sergey Shulyak is the CEO of a marketing agency who provided insights on the financial impact of the pharmacy network closures.
6
Russia:
Sergey Shulyak is the CEO of DSM Group who explained the recovery of classic drug consumption after the pandemic.
8